Vigil Neuroscience (VIGL)
(Real Time Quote from BATS)
$3.26 USD
+0.02 (0.62%)
Updated Aug 8, 2024 01:24 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VIGL 3.26 +0.02(0.62%)
Will VIGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VIGL
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade
Other News for VIGL
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
Vigil Neuroscience publishes new data on CSF1R gene variants
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
Buy Rating Affirmed on Vigil Neuroscience’s VG-3927 Based on Positive Phase 1 Results and Strong Industry Outlook
Vigil Neuroscience announces interim data from ongoing Phase 1 trial on VG-3927